These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23390377)

  • 1. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
    Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
    Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
    Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
    Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
    Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
    Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structural complexity of the human BORIS gene in gametogenesis and cancer.
    Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
    PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
    Hoffmann MJ; Müller M; Engers R; Schulz WA
    Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
    Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
    Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of hTERT and stemness genes in BORIS/CTCFL positive cells isolated from embryonic cancer cells.
    Alberti L; Renaud S; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2014; 9(10):e109921. PubMed ID: 25279549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
    Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
    Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
    Zhao J; Wang Y; Liang Q; Xu Y; Sang J
    J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic activation of POTE genes in ovarian cancer.
    Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR
    Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
    Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
    Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
    Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
    Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTCF and BORIS in genome regulation and cancer.
    Marshall AD; Bailey CG; Rasko JE
    Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
    Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
    PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
    Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
    Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.